Holen Sie sich die Stockscreener-App
3.73
1.63%
0.06
Handel nachbörslich:
3.65
-0.08
-2.14%
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
IXHL Forecast — Price Target — Prediction for 2027 - TradingView
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
IXHL Should I Buy - Intellectia AI
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Healthcare receives A$6m R&D tax incentive payment - Investing.com UK
Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com - Investing.com Nigeria
Incannex Healthcare Secures Major Non-Dilutive R&D Funding - TipRanks
Incannex Healthcare Secures Over A$11 Million in Non-Dilutive Capital Through Australian R&D Tax Incentive Program - Quiver Quantitative
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility - The Manila Times
Incannex lines up A$11m in non‑dilutive cash to advance IHL‑42X study - Stock Titan
Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding - TradingView
Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan
Incannex Healthcare: Target Price Consensus and Analysts Recommendations | IQI | AU000000IHL8 - marketscreener.com
Incannex Healthcare Gains Independent Buy-Rated Research Coverage - TipRanks
Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan
Incannex Healthcare: Alliance Global Partners Starts Coverage with $18 Price Target - TradingView
Alliance Global initiates Incannex (IXHL) equity research coverage on key drug pipeline - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
$Incannex Healthcare (IXHL.US)$ [Onlooker][OK] - Moomoo
INCANNEX HEALTHCARE INC (IXHL) Stock Chart - ChartMill
Incannex Healthcare Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D InvestmentOperating Income Trends - newsline.com
Why Are ASX Cannabis Stocks Drawing Fresh Attention? - Kalkine Media
IXHL Q1 2026 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - newsline.com
Incannex Healthcare (IXHL) Dips 3.27% as Stock Tests Near-Term SupportCall Wall - newsline.com
Incannex Healthcare | 8-K: Current report - Moomoo
Incannex Shares Surge Following Promising Sleep Apnea Trial Data - MSN
Incannex reactivates share repurchase program, cites ‘significant disconnect’ between its market cap and financial strength - MSN
IXHL Technical Analysis | Trend, Signals & Chart Patterns | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill
Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA - Sleep Review
Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary - TradingView
IXHL: Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases - TradingView
Incannex Healthcare (NASDAQ: IXHL) grows cash to $74.5M amid $16.8M loss - Stock Titan
Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea - TradingView
Incannex launches DReAMzz study for sleep apnea treatment - Investing.com UK
Incannex Healthcare Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea, Advancing Late-Stage Development 1 - Minichart
Incannex launches DReAMzz study for sleep apnea treatment By Investing.com - Investing.com South Africa
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea - The Manila Times
Incannex Healthcare Inc. Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Treatment - Quiver Quantitative
New sleep apnea drug enters dose-test in Incannex DReAMzz trial - Stock Titan
Incannex Launches DReAMzz Study for IHL-42X Sleep Apnea - TipRanks
Incannex Healthcare commences DReAMzz study for IHL-42X, 14 sites onboarded - TradingView
Incannex (IXHL) launches DReAMzz dose-optimization study of IHL-42X for sleep apnea - Stock Titan
IXHL Q3'26 Earnings: EPS estimate is (0.60) USD - TradingView
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):